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Diabetes during pregnancy results in congenital mal-
formations and long-term postnatal diseases. Experimen-
tal models are still needed to investigate the mechanism
responsible for these alterations. Thus, by the adminis-
tration of different doses of streptozotocin (STZ) (0, 25,
30, or 35 mg/kg body weight, intravenous) at the onset
of pregnancy in rats, the present study sought an appro-
priate animal model for this pathology. At day 6 of preg-
nancy, plasma glucose was progressively higher with an in-
creasing STZ dose, and in rats receiving the 35-mg dose,
2 subgroups were detected: some animals had plasma glu-
cose levels above controls but below 200 mg/dL (mildly di-
abetic, MD), whereas others had levels above 400 mg/dL
(severely diabetic, SD). At day 20 of pregnancy, the MD
rats had normal glycemia, but after an oral glucose load
(2 g/kg body weight), plasma glucose increased more and
insulin increased less than in controls. The SD rats main-
tained their hyperglycemia and had a greatly impaired
oral glucose tolerance. At day 20, fetuses of SD dams were
fewer, weighed less, and had enhanced plasma glucose and
triglycerides and decreased insulin, whereas those from
MD dams did not differ from controls. At birth, newborns
from MD dams had higher body weight, plasma insulin,
and liver triglycerides as well as total body lipid concentra-
tions than controls, and on day 21, remained macrosomic
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and showed higher plasma glucose and liver triglyceride
concentrations.At70daysofage,offspringofMDdamshad
impaired oral glucose tolerance but normal plasma insulin
change in the case of females, whereas plasma insulin in-
creased less in males. These alterations were manifest more
in those offspring from dams that had >50% macrosomic
newborns than in those from dams that had <50% macro-
somicnewborns.Inconclusion,whereasourMDratsmimic
the changes taking place in gestational diabetic women and
show the long-term risk of macrosomia, the SD rats are
more similar to uncontrolled diabetics. Thus these two rat
models, obtained with moderate amounts of STZ, could be
used to study the pathophysiological consequences of these
different diabetic conditions.
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Diabetes of the mother during pregnancy causes an abnor-
mal intrauterine metabolic and hormonal milieu that results in
congenital malformations and neonatal hypoglycemia [1, 2]. It
also enhances the risk of short- and long-term postnatal dis-
ease, including macrosomia [3, 4], an increase in the frequency
of insulin resistance, gestational diabetes [5, 6], and obesity
[7–9]. Besides hyperglycemia, the multifactorial metabolic de-
rangement resulting from maternal insulin deﬁciency seems to
play an important role in those fetal disturbances [10]. Studies
in humans that explore the responsible mechanism for these
alterations are limited not only by ethical reasons but also by
the multiplicity of uncontrolled variables that may modify the
intrauterineenvironmentandcausepotentialeffectsoncongen-
ital malformations, such as feeding behavior, socioeconomic
factors, nutritional status, and genetic factors. Thus, there is a
need for appropriate animal models. Models that use glucose
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infusions to produce maternal hyperglycemia do not duplicate
maternal insulin deﬁciency [11, 12]. Because streptozotocin
(STZ)-induced diabetes is now well characterized [13], this
antibiotic agent has been widely used for inducing pancreatic
β-cell degranulation and necrosis in pregnant rats. Whereas in
some studies, STZ has been administered before the onset of
pregnancy [14–20], in others, the drug is administered just at
the onset [21–25], and even given on days 5 to 8 of gestation
[26]. The ﬁrst procedure, however, causes difﬁculties in ob-
taining successful mating, making it necessary to administer
therapeuticinsulintreatmentduringthematingperiod[14–17].
The last procedure is not free of secondary effects, because
STZ is known to cross the placenta [27] and therefore may
havedirecteffectsonembryodevelopment.Thetreatmentwith
STZ on the day of onset of pregnancy is, nevertheless, the most
convenient, because it does not affect the mating period and it
certainly does not disturb the early stages of embryo develop-
ment because of its very short half-life [28]. The role of STZ
treatmentindevelopingdiabetesinthepregnantratsanditscon-
sequences in fetal or newborn body weight is highly variable,
rangingfromdevelopingmicrosomia[21,29–31],tonochange
[21, 32, 33] or to macrosomia [26, 34–36]. Whereas a positive
correlation between maternal glycemia and fetal weight was
found in mildly diabetic rats, a negative correlation between
these two variables was found in severely diabetic rats [30].
Thus the severity of the diabetes attained determines the type
of response. The difﬁculties of obtaining a mild-to-moderate
hyperglycemia as a response to STZ treatment has forced re-
searchers to look for experimental strategies such as the syn-
geneic islet transplant [37, 38] or insulin pump implantation
after treatment with STZ [39], which, aside from their intrin-
sic difﬁculty, are far from mimicking the diabetic condition in
humans. More recently, a model of gestational diabetes based
on the offspring of uteroplacental insufﬁcient pregnant rats has
beendescribed[40],showingthatdefectsinglucosehomeosta-
sisintheoffspringofdiabeticpregnantratsleadtothedevelop-
ment of diabetes later in life. In view of difﬁculties in obtaining
ananimalmodelofdiabeticpregnancy,thepresentstudyaimed
to deﬁne the dose of STZ to obtain an easy and reproducible
animal model of mildly diabetic pregnancy, by administrating
different doses of STZ at the onset of pregnancy in rats and
studying them at different time points, and to study some of the
short- and long-term pathophysiological consequences in the
offspring.
MATERIAL AND METHODS
FemaleSprague-Dawleyratsfromourowncolony,weighing
170to180g,housedinatemperature-controlledroom(21◦Cto
23◦C)with12-hourlight-darkcyclesandfedastandardnonpu-
riﬁed diet (B&K Universal, Barcelona, Spain) ad libitum, were
mated. The day that spermatozoids appeared in vaginal smears
(day 0 of pregnancy), they were intravenously treated with 25,
30,or35mgSTZ(Sigma,St.Louis,MO,USA)/kgbodyweight,
dissolvedin50mMcitratebuffer,pH4.5.Controlanimalswere
runinparallel,andreceivedthemedium.Theexperimentalpro-
tocol was approved by the Animal Research Committee of the
UniversitySanPablo–CEUinMadrid,Spain.Onday6ofpreg-
nancy, animals were weighed and blood was collected from the
tail into tubes containing Na2-EDTA. On day 20 of pregnancy,
some rats from controls and from those that were treated with
the35-mgSTZdosewerekilledbydecapitationandbloodfrom
theneckwoundwascollectedintotubescontainingNa2-EDTA.
The two uterine horns were immediately excised and weighed
with their contents to obtain the whole conceptus weight. This
value was subtracted from the rat’s total body weight to obtain
the net maternal body weight. Blood from all the fetuses com-
ing from the same dam was pooled and processed in parallel to
that of the adults. In another set of rats from the same groups
(e.g., controls and those treated with the 35-mg STZ dose), an
oral glucose tolerance test (OGTT) was performed as follows:
after collecting blood from the tail (0 time), the rats received
an oral load of 2 g of glucose/kg body weight, and blood was
collected at 7.5, 15, 22.5, 30, and 60 minutes. Rats showing
a moderate diabetic condition (i.e., normal basal glucose but
impaired OGTT) and controls were allowed to deliver, and the
newbornpupsimmediatelyweighedthereafter.Littersweread-
justed at random to 9 pups per dam and allowed to suckle. The
day of birth all the remaining pups from each litter were decap-
itated and blood collected from the neck into tubes containing
Na2-EDTA. Livers were immediately excised and placed into
liquid N2 and kept at −80◦C until processed for triglyceride
(TG) analysis, as previously described [41]. Other newborn
pups were directly placed into liquid N2 and stored at −80◦C
until processed for lipid extraction [42] to determine total lipid
contentbyweightofdriedlipidextracts.Onday21oflactation,
pups were weaned. They were weighed and some of the pups
from each litter were killed to collect blood as above. Livers
were immediately excised and placed into liquid nitrogen and
kept at −80◦C until processed for lipid extraction [42]. TGs
were quantiﬁed in aliquots of lipid extracts after image anal-
ysis and separation by 1-dimensional thin-layer chromatogra-
phy (TLC) [43] using the G5-700 Bioimage TLC scanner of
Bio-Rad (Hercules, CA, USA) as previously described [41].
The remaining pups were allow to progress until 70 days old,
when they were subjected to an OGTT as above.
Plasma was immediately separated after blood collections
by centrifugation at 3000 rpm for 20 minutes at 4◦C, and was
keptat−80◦Cuntilanalysisforglucose,TGs,andimmunoreac-
tive insulin by using commercial kits (Boehringer-Mannheim,MODERATE DIABETES IN PREGNANT RATS 109
TABLE 1
Plasma glucose and body weight at day 6 of gestation of control rats and rats that had received different doses
of STZ (mg/kg body weight) at the onset of pregnancy
STZ-35∗
Controls STZ-25 STZ-30 MD SD
Blood glucose (mg/dL) 126 ± 3a (14) 141 ± 3a (12) 160 ± 5b (15) 169 ± 8b (17) 424 ± 15c (5)
Body weight (g) 221 ± 4a (14) 219 ± 3a (12) 216 ± 4a (15) 216 ± 4a (17) 201 ± 3a (5)
Note. Values are means ± SEM. The number of observations is in parenthesis. Tukey’s test was used to determine
differences between groups after ANOVA. Different superscripts in a row indicate signiﬁcance differences (P <. 05).
∗Those receiving the 35-mg/kg dose are differentiated into two groups: MD = mildly diabetic; SD = severely diabetic.
Germany; Menarini Diagnostics, Italy; and Mercodia AB,
Sweden, respectively).
Results were expressed as means±SEM. Values were ana-
lyzedby1-wayanalysisofvariance(ANOVA),usingcomputer
software (Systat Version 5.03, Wilkinson, Evanston, IL, USA).
When treatment effects were signiﬁcantly different (P <. 05),
speciﬁcmeansweretestedbyTukey’stest.Differencesbetween
the 2 groups were analyzed by Student’s t test.
RESULTS
At day 6 of gestation, plasma glucose was progressively
higher in rats that received the 25, 30, or 35 mg STZ dose/kg at
the onset of gestation, although the difference with the controls
wassigniﬁcantonlyinthosereceivingthe30-mgdoseandover
(Table1).Inratsthathadreceivedthe35-mgdose,2clearlydif-
ferentiated subgroups could be detected: some animals showed
a signiﬁcant but moderate increase in plasma glucose (below
the 200 mg/dL value), and this subgroup was named “mildly
diabetic”(MD).Intheothers,plasmaglucoselevelswereabove
TABLE 2
Plasma glucose, insulin, and triglycerides, and body weight of mothers and fetus at day 20 of gestation of control
rats and rats that had received 35 mg STZ/kg body weight at the onset of pregnancy
Controls MD∗ SD∗
Maternal plasma glucose (mg/dL) 89 ± 3a (10) 83 ± 4a (13) 188 ± 33b (9)
Maternal plasma triglycerides (mg/dL) 416 ± 68a (10) 384 ± 21a (13) 1043 ± 83b (9)
Maternal plasma insulin (µU/mL) 24.7 ± 3.8a (9) 17.3 ± 2.9a (12) 26.6 ± 4.3a (6)
Net maternal body weight (free of conceptus) (g) 279 ± 4a (10) 263 ± 3a,b (15) 254 ± 10b (9)
Fetal plasma glucose (mg/dL) 44 ± 3a (10) 64 ± 11a (15) 223 ± 35b(9)
Fetal plasma triglycerides (mg/dL) 69 ± 2a (10) 72 ± 2a,b (15) 79 ± 3b(9)
Fetal plasma insulin (µU/mL) 113 ± 10a,b (10) 159 ± 13b (15) 87 ± 17a (9)
Fetal body weight (g) 4.70 ± 0.04a (8) 4.62 ± 0.08a (11) 3.94 ± 0.12b (8)
Note. Values are means ± SEM. Fetal blood samples from each mother were pooled, and fetal weight values correspond to the
means of all the fetuses from the same mother. The number of observations is in parenthesis. Tukey’s test was used to determine
differences between groups after ANOVA. Different superscripts in a row indicate signiﬁcant differences (P <. 05).
∗Rats dosed with 35 mg STZ/kg body weight were separated into mildly diabetic (MD) and severely diabetic (SD) based on
glycemia at day 6 of pregnancy.
400mg/dLandthisgroupwasnamed“severelydiabetic”(SD).
At this time of pregnancy, body weights did not differ between
the groups (Table 1). As shown in Table 2, at day 20 of ges-
tation, rats that had received the 35-mg STZ dose and were
considered MD showed net maternal body weight (free of con-
ceptus), plasma glucose, insulin, and TG levels, and fetal body
weight that did not differ from those of controls. However, in
comparison to both control and MD, rats that had received the
same STZ dose (35 mg/kg) but were considered SD showed
decreased net maternal body weight and fetal body weight,
but increased plasma glucose and TG levels, as well as fetal
plasma glucose. Whereas fetal plasma insulin appeared lower
in this group than in MD rats, fetal plasma TGs were higher
than controls (Table 2). No difference in either of these vari-
ableswasfoundatday20ofgestationinthoseratsthatreceived
the 25- or 30-mg STZ dose as compared to either controls, or
ratsreceivingthe35-mgdoseconsideredMD(datanotshown).
At day 20 of gestation, some rat mothers from the MD, SD,
and control groups were subjected to an OGTT. As shown in
Figure 1, blood glucose levels were highly augmented in the110 I. L´ OPEZ-SOLDADO AND E. HERRERA
FIGURE 1
Plasma glucose (A) and insulin (B) levels at different times after an oral glucose load (2 g/kg body weight) at day 20 of
pregnancy in mildly diabetic (MD) and severely diabetic (SD) rats that had received 35 mg/kg of streptozotocin at the onset of
pregnancy, as compared to nontreated controls. Signiﬁcant differences versus controls at each time point are shown by the letters:
a, P <. 05; b, P <. 01; c, P <. 001. The number of rats per group are shown in parenthesis.
SD rats as compared to controls at all time points studied. Al-
though plasma insulin did not differ between the 2 groups at
the 0- and 60-minute time point values at 7.5, 15, 22.5, and
30minutesweresigniﬁcantlylowerintheSD,whichatnotime
showed any increase in plasma insulin as compared to basal
levels (time 0). In the MD rats, although basal blood glucose
levels did not differ from controls, values at 7.5, 15, 22.5, 30,
and 60 minutes were signiﬁcantly higher than in controls, andMODERATE DIABETES IN PREGNANT RATS 111
TABLE 3
Body weight, plasma glucose and insulin, liver triglycerides, and total lipids in newborn (the day of birth) and 21-day-old
pups of mildly diabetic (MD) and control rats
Newborns 21-day-old pups
Controls MD Controls MD
Body weight (g) 6.02 ± 0.04 (98) 6.49 ± 0.06c (115) 41.8 ± 0.4 (53) 44.5 ± 0.5c (71)
Plasma glucose (mg/dL) 86 ± 4 (10) 103 ± 9 (8) 158 ± 3 (13) 169 ± 3a (11)
Plasma insulin (µU/mL) 5.5 ± 1 (7) 13.9 ± 3.6a (6) 24.1 ± 1.4 (13) 21.5 ± 1.9 (16)
Liver triglycerides (mg/g tissue) 2.42 ± 0.09 (6) 16.16 ± 6.58a (5) 2.7 ± 0.3 (12) 3.8 ± 0.2b (11)
Total lipids (mg/g) 19.8 ± 2.45 (9) 28.9 ± 2.1a (8) ND ND
Note. Values are means ± SEM. aP <. 05; bP <. 01; cP <. 001 versus the corresponding controls. The number of observations is in
parenthesis. ND, not determined.
plasma insulin levels were lower at 7.5, 15, and 22.5 minutes,
with no difference between these 2 groups at 0, 30, or 60 min-
utes. In fact, contrasting with the SD rats, in the MD rats there
was a signiﬁcant increase in plasma insulin levels after the oral
glucoseload,althoughinthepeaktime,valueswerewellbelow
those of controls (Figure 1).
WhenMDandcontrolratswereallowedtodeliver,newborns
weighed more and plasma insulin levels were higher in the ﬁrst
group. Blood glucose did not differ between the 2 groups and
liver TG and total body lipid concentrations were higher in
newborns from MD rats than in controls (Table 3). Some of the
pups from these two groups were allowed to suckle and studied
at the time of weaning (21 days old). At this time, body weight
values remained higher in pups from MD rats than in controls,
and although plasma glucose levels and liver TG concentration
were also higher in pups from MD rats, plasma insulin levels
did not differ between the 2 groups (Table 3).
Some pups from control and MD dams were weaned at the
age of 21 days old, and studied at the age of 70 days. At this
time, female rats coming from MD dams were still heavier
(body weight 235.3 ± 3.3g ,n= 18) than those from controls
(225.2 ± 3.6g ,n= 12, P <. 05), whereas body weight in
males did not differ (412.9 ± 7.4g ,n= 28, in those from
MD dams and 427.7 ± 7.3g ,n= 19, in those from controls,
nonsigniﬁcant[NS]).However,bothfemalesandmalesshowed
an altered glucose/insulin relationship. As shown in Figure 2,
female pups coming from MD dams had an impaired OGTT
as seen by the greater increase in plasma glucose, although
plasma insulin levels did not differ as compared to the controls.
As shown in Figure 3, male pups coming from MD dams show
not only an impaired OGTT as a result of a greater increase in
plasma glucose, but also a lower increase in plasma insulin, as
compared to those coming from control dams.
In view of the differences found in the OGTTs, it was de-
cided to separate values found in 70-day-old pups into those
coming from MD dams that had more than 50% of the litter
with macrosomia at delivery (estimated as pups whose birth
weights were 1.7 SD greater than the mean birth weight of the
control pups [35]) and those that had less than 50% of macro-
somic pups. As shown in Figure 4, only female offspring from
MD dams having litters with more than 50% macrosomic pups
had impaired OGTT, whereas glucose tolerance did not dif-
fer in those from MD dams having litters with less than 50%
macrosomic pups. In the case of males, as shown in Figure 5,
the fact that they come from MD dams having either more or
less than 50% macrosomic pups at the time of delivery did
not modify the impaired glucose tolerance. Only those com-
ing from dams having more than 50% of the pups macro-
somic showed decreased plasma insulin as compared to the
controls.
DISCUSSION
Inadditiontoshowingthedifﬁcultiesinobtainingamoderate
and dose-dependent response to STZ treatment in rats, as seen
by the normalization of the response in those rats receiving the
30-mg dose subsequent to an initial hyperglycemia, the present
results also show that the degree of the response varies among
rats after receiving the 35-mg/kg dose. Whether this different
response was due to genetic variations of rats from the same
strain remains to be established. Present ﬁndings also show
that (i) neonatal macrosomia in offspring of MD rats is asso-
ciated to neonatal hyperinsulinemia and mainly corresponds to
an accumulation of body lipids; (ii) the enhanced body weight
in the newborns from MD dams is maintained until the end
of weaning, and in the case of female rats, until 70 days old;
and (iii) a long-term altered OGTT is shown in the 70-day-old
offspringfromMDdams,whichisspeciallymanifestedinthose
coming from dams having macrosomic litters rather than from
normosomic, suggesting that macrosomia itself is an important112 I. L´ OPEZ-SOLDADO AND E. HERRERA
FIGURE 2
Plasma glucose (A) and insulin (B) levels at different times after an oral glucose load (2 g/kg body weight) at 70 days of age in
female offspring of mildly streptozotocin diabetic (MD) and control rats. Signiﬁcant differences versus controls at each time
point are shown by the letters: a, P <. 05; b, P <. 01; c, P <. 001. The number of rats per group are shown in parenthesis.
risk factor for long-term disturbance in the glucose/insulin
relationship.
Different from what occurs in humans, macrosomia in the
offspring of MD rats was found only after birth. This ﬁnd-
ing agrees with the fact that any previously reported effort
to develop macrosomia in the offspring of STZ diabetic rats
was obtained postnatally [26, 34–36, 44] and very rarely be-
fore birth, which agrees with the fact that in humans, fat depotMODERATE DIABETES IN PREGNANT RATS 113
FIGURE 3
Plasma glucose (A) and insulin (B) levels at different times after an oral glucose load (2 g/kg body weight) at 70 days of age in
male offspring of mildly streptozotocin diabetic (MD) and control rats. Signiﬁcant differences versus controls at each time point
are shown by the letters: a, P <. 05; b, P <. 01; c, P <. 001. The number of rats per group are shown in parenthesis.
accumulation takes place intrauterinely, whereas in rats this
occurs after birth (for a review, see [45]). An additional re-
quirement for developing neonatal macrosomia in the mildly
diabeticratseemstobethepresenceofperinatalhyperinsuline-
mia, which must be a consequence of maternal hyperglycemia.
Normoglycemia was, however, seen here in the MD rat at day
20 of pregnancy. Whereas the fetuses were hyperinsulinemic,
a clear impaired maternal oral glucose tolerance was present114 I. L´ OPEZ-SOLDADO AND E. HERRERA
FIGURE 4
Plasma glucose (A) and insulin (B) levels at different times after an oral glucose load (2 g/kg body weight) at 70 days of age in
female offspring of mildly streptozotocin diabetic (MD) rats that had either more or less than 50% of their litter macrosomic
and control rats. Signiﬁcant differences versus controls at each time point are shown by the letters: a, P <. 05; b, P <. 01;
c, P <. 001. The number of rats per group are shown in parenthesis.
in the dams. This indicates that whenever the mother eats, she
develops hyperglycemia that will be followed by fetal hyper-
glycemic episodes and subsequent pancreatic stimulus. This
action, plus the well-known enhanced pancreatic β-cell sensi-
tivitytotheglucosestimulus[21],justiﬁesthehyperinsulinemia
seen in the offspring of mildly diabetic rats around birth.
EnhancedbodyweightintheoffspringofMDratsremained
until weaning, and in the case of females, it was maintainedMODERATE DIABETES IN PREGNANT RATS 115
FIGURE 5
Plasma glucose (A) and insulin (B) levels at different times after an oral glucose load (2 g/kg body weight) at 70 days of age in
male offspring of mildly streptozotocin diabetic (MD) rats that had either more or less than 50% of their litter macrosomic
and control rats. Signiﬁcant differences versus controls at each time point are shown by the letters: a, P <. 05; b, P <. 01;
c, P <. 001. The number of rats per group are shown in parenthesis.
until 70 days of age. This ﬁnding differs with previous reports
where augmented body weight was maintained in both females
and males until adulthood in macrosomic pups from mildly
STZ diabetic rats [26, 34, 46]. However, in these studies, only
pups showing macrosomia at birth were included in the study,
and even on one occasion, nonmacrosomic pups born to STZ-
treated dams were added to the control group [46]. All exper-
imental designs allowed the respective authors to determine116 I. L´ OPEZ-SOLDADO AND E. HERRERA
the consequences of postnatal macrosomia but had impeded
determination of the speciﬁc long-term consequences of the di-
abetic intrauterine milieu. Because no pup selection was made
at birth in the present study, it was possible here to clearly
determine the long-term consequences of the intrauterine dia-
betic environment on the OGTT performed on the 70-day-old
pups.
A long-term glucose/insulin alteration was seen in the off-
spring of the MD rats as shown by their impaired oral glucose
tolerance at 70 days old. Although in the case of males, such
alteration was consistently seen in all pups independent of their
body weight at birth, in females, this was seen only in those
coming from litters having more than 50% macrosomic pups.
Small but signiﬁcant differences in the OGTT were also pre-
viously found between macrosomic males and females coming
from MD rat mothers as compared to those in controls [34, 46],
although in these reports only macrosomic pups were included
in the study. Thus, besides showing the long-term alteration
in the glucose/insulin relationship in the offspring of MD rats,
whichconﬁrmspreviousreports[21,24,30,38,47],thepresent
study shows an impaired glucose tolerance in the presence of
normal insulin levels in the adult female offspring of MD rats
that had a high incidence of macrosomic pups but not in those
having normosomic pups. The present ﬁndings, therefore, al-
low us to propose that macrosomia itself in the offspring of
MD mothers is a risk factor for long-term disturbance of glu-
cose/insulin relationships. Besides, these ﬁndings demonstrate
the similarity to what happens in humans: the main component
of macrosomia corresponds to an accumulation of fat depots,
probably subsequent to perinatal hyperinsulinemia. It was also
seen here that an enhanced liver TG concentration contributes
to the total body fat accumulation in newborn pups from MD
pups. This may also differ from humans, because lack of adi-
pose tissue development in the newborn rat converts its liver
into a temporal TG depot site, which is facilitated by the in-
duction of lipoprotein lipase (LPL) activity taking place in the
liver during the perinatal phase and the suckling period [45].
The condition of the SD pregnant rats, despite the mod-
erate STZ dose administered, also deserves attention. These
animals have normal basal insulin levels but greatly impaired
insulinotropicresponsetothestimulusoftheglucoseload,indi-
catingamajoralterationinβ-cellfunction,whichisresponsible
for their hyperglycemia and exaggerated hypertriglyceridemia.
Maternal hyperglycemia is also responsible for fetal hyper-
glycemia, which would have caused a prolonged fetal β-cell
stimulus, resulting in depletion of fetal pancreatic insulin and
subsequent hypoinsulinemia, contributing to the decrease in
fetal body weight. Maternal hypertriglyceridemia may addi-
tionally be responsible for the increments in fetal plasma TG
concentrations. Although TGs do not directly cross the placen-
talbarrier[48],theplacentahasmechanismsbywhichmaternal
plasma TGs correlate with those in the fetus [49].
In summary, whereas the condition of those SD rats may
be comparable to that found in uncontrolled pregnant diabetic
women, where microsomia is most often found [50, 51], the
MD rats mimic most of the changes taking place in gestational
diabetic women. Thus, both diabetic populations obtained here
with moderate amounts of STZ in rats may be used as ap-
propriate experimental models to study the pathophysiological
consequences of uncontrolled or moderately diabetic pregnant
women, rather than the use of higher STZ doses that cause
a diabetic condition in the rat that is quite different from the
situation in pregnant women. Further, present ﬁndings show
the long-term alteration of the glucose/insulin axis of the off-
spring of MD rats, magniﬁed when they were macrosomic at
birth.
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